Shield the healthy cells, attack the cancer
We aim to cure blood cancers through cell and genome engineering
Vor Bio is developing a proprietary platform built on Hematopoietic Stem Cell (HSC) biology, genome engineering, and CAR-T Cells.
We’re applying the latest scientific advancements to fight AML and other blood cancers in a new way.
Our proprietary platform combines genome engineering, Hematopoietic Stem Cell (HSC) biology, and CAR-T cells to solve urgent unmet medical needs for patients with blood cancers.
We aim to transform treatment by shielding the healthy blood cells and only attacking the cancer cells with targeted therapies post-transplant.
We are currently conducting several trials for AML and MDS to further investigate our promising approach to shield healthy cells.
Our approach shields healthy cells enabling multiple modalities and therapies post-transplant, including ADCs and CAR-Ts, which by themselves are highly toxic.
By shielding healthy cells, we are aiming to delay or prevent relapse and enable cures for patients with AML and other blood cancers.
Our clinical trials for AML and MDS are actively recruiting patients.
Come be a part of a team that is developing a unique approach to one of medicine’s greatest challenges—eradicating cancer.